Health
Novo’s Rybelsus Plant Had Bacteria Contamination, FDA Says
- July report says company’s actions have been inadequate
- Analysts don’t expect the notice to affect supply of drugs
This article is for subscribers only.
US regulators said Novo Nordisk A/S failed to properly investigate bacterial contamination earlier this year at a plant that makes one of its best-selling diabetes drugs.
Bacteria showed up in batches of semaglutide, the active ingredient in the diabetes medicine Rybelsus, on at least three occasions between February and June when inspectors visited the plant in Clayton, North Carolina, according to a US Food and Drug Administration report obtained through a Freedom of Information Act request.